As an intranasal respiratory vaccine, INFORCE 3^® causes a local immune response with viral antibodies produced in the nasal passage where BRSV, IBR and PI₃ are most likely to enter the animal’s system.

INFORCE 3^® is the first commercially-available intranasal respiratory vaccine to help protect against respiratory disease caused by BRSV, while also protecting against IBR and PI₃, to help get cattle off to a healthier, more productive start.

INFORCE 3 has a six-month duration of immunity claim for IBR protection, and a single-nostril administration claim. Additional research also demonstrated no maternal antibody interference for IBR and BRSV.^2,3

Safe for all ages, types and classes of cattle

INFORCE 3^® is safe for use in all types, ages and classes of cattle. INFORCE 3 was demonstrated safe for use in very young, high-stress calves; weaned and high-stress stocker calves; and pregnant heifers and cows.

The Science Behind Effective Control

• Intranasal administration works with the animal's immune system for fast, effective response
• Helps prime the immune system for a memory response to subsequent vaccinations as well as disease challenges
• Contains proprietary, temperature-sensitive IBR and PI₃ strains that replicate most effectively in the upper respiratory tract
• Stimulates interferon release for protection
• Helps deliver a healthy start for young dairy calves

Proven Respiratory Disease Protection

• In two different studies, all calves vaccinated with INFORCE 3 survived severe BRSV challenges in which 100% and 90% of unvaccinated controls either died or had to be humanely euthanized.^4,5
• INFORCE 3 was shown to help prevent respiratory disease caused by IBR and PI₃ and reduce level and duration of viral shedding caused by IBR and PI₃.^6-8
• A study comparing INFORCE 3 and TSV-2^® demonstrated that vaccinating cows and heifers with INFORCE 3  prior to freshening helped support overall positive production:
• 205 pounds more milk per cow per lactation⁹
• Increased income per cow⁹

Directions

Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, mix well and administer 2 mL intranasally using a cannula. Place the 2-mL dose in a single nostril or place 1-mL in each nostril. 

Calves vaccinated before the age of 6 months should be revaccinated after 6 months of age to avoid possible maternal antibody interference with immunization. Annual revaccination with a single dose is recommended. 

For further advice on revaccination frequency, consult your veterinarian.

PRECAUTIONS:

1. Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

2. Use entire contents when first opened.

3. Sterilized syringes should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

4. Inactivate unused contents before disposal.

5. Do not vaccinate within 21 days before slaughter.

6. Contains gentamicin as preservative.

7. Fetal health risks associated with the vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined during clinical trials conducted for licensure. Appropriate strategies to address the risks associated with modified live vaccine use in pregnant animals should be discussed with a veterinarian.

8. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

References

1. Based on number of doses and overall sales of respiratory vaccines. Animalytics Segment Data, Biologicals Therapeutic Category, Ending MAT May 2021.
2. Mahan SM, Sobecki B, Johnson J, et al. Efficacy of Intranasal Vaccination With a Multivalent Vaccine Containing Temperature-Sensitive Modified-Live Bovine Herpesvirus Type 1 for Protection of Seronegative and Seropositive Calves Against Respiratory Disease. J Am Vet Med Assoc. 2016;248(11):1280-1286.
3. Ellis JA, Gow SP, Mahan S, Leyh R. Duration of Immunity to Experimental Infection With Bovine Respiratory Syncytial Virus Following Intranasal Vaccination of Young Passively Immune Calves. J Am Vet Med Assoc. 2013;243(11):1602-1608.
4. Data on file, Study Report No. 3131R-60-08-557, Zoetis Inc.
5. Data on file, Study Report No. 3131R-60-09-669, Zoetis Inc.
6. Data on file, Study Report No. 3131R-60-08-548, Zoetis Inc.
7. Data on file, Study Report No. 3131R-60-09-720, Zoetis Inc.
8. Data on file, Study Report No. 3131R-60-08-568, Zoetis Inc.
9. Data on file, Study Report No. 10PETINF01, Zoetis Inc.